Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medical education in low- and middle-income countries must be innovated without neglecting its foundational principles.

Frontiers in medicine·2026
Same author

Hepatitis D virus infection in sub-Saharan Africa: a scarcely studied, yet important issue.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Long-acting injectable cabotegravir/rilpivirine in a pregnant woman living with HIV with hyperemesis gravidarum:a case report and review of literature.

International journal of STD & AIDS·2026
Same author

Hepatitis C virus and HIV transmission: parenteral (including percutaneous) routes are still relevant and must receive due attention.

Frontiers in public health·2026
Same author

Community acquired bacteremia in older adults: International and prospective infectious diseases-international research initiative (ID-IRI) study.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Research priorities for data science and artificial intelligence in global health: an international consensus exercise.

The Lancet. Global health·2026

Related Experiment Video

Updated: Jul 10, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

[CD4+ guided interruption HAART in HIV patients].

Dario Antolini1, Massimiliano Lanzafame, Emanuela Lattuada

  • 1Unità Operativa di Malattie Infettive, Dipartimento di Patologia Generale, Ospedale Policlinico G.B. Rossi, Verona.

Recenti Progressi in Medicina
|November 1, 2007
PubMed
Summary

CD4+-guided highly active antiretroviral therapy (HAART) interruption is effective and safe for select HIV+ patients, allowing a mean 18-month treatment break without serious adverse events. Lower CD4+ nadir levels may predict shorter interruption periods.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jul 10, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Area of Science:

  • Immunology
  • Virology
  • Clinical Medicine

Context:

  • Highly active antiretroviral therapy (HAART) is standard for managing Human Immunodeficiency Virus (HIV).
  • Treatment interruption strategies are being explored to reduce long-term toxicity and cost.
  • Patient selection and monitoring are crucial for safe interruption protocols.

Purpose:

  • To evaluate the efficacy and safety of a CD4+-guided intermittent highly active antiretroviral therapy (HAART) strategy in Human Immunodeficiency Virus (HIV)-positive patients.
  • To determine the duration of treatment interruption achievable and the reasons for reintroduction of therapy.

Summary:

  • Forty-six HIV-positive patients with CD4+ counts >500/microliter and undetectable viral load for at least 3 years underwent CD4+-guided HAART interruption.
  • The strategy allowed a mean treatment interruption of 18 months.
  • No deaths or opportunistic infections occurred; reintroduction of HAART was triggered by CD4+ count decline (<200/microliter), acute retroviral syndrome, or patient-specific factors.
  • A low CD4+ nadir level was associated with a shorter treatment interruption period.

Impact:

  • This CD4+-guided HAART interruption approach demonstrates a safe and effective method for managing HIV, potentially reducing long-term treatment burden.
  • Findings support personalized treatment strategies in HIV management.
  • Further research can optimize patient selection and monitoring for sustained treatment-free intervals.